A study to find out if a hormonal birth control called Drospirenone, changes the bone density in adolescent and adult wome
- Conditions
- Oral contraceptionMedDRA version: 21.0Level: PTClassification code 10049470Term: Bone density decreasedSystem Organ Class: 10022891 - InvestigationsTherapeutic area: Body processes [G] - Bones and nerves physological processes [G11]
- Registration Number
- EUCTR2020-000412-30-PL
- Lead Sponsor
- Chemo Research S.L.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- Female
- Target Recruitment
- 1362
1. Female subjects with regular menstrual cycles (postmenarcheal for at least two years and premenopausal) aged 14 to 45 years. Female subjects aged between 14 to 17 years (inclusive) will only be included provided that
a. Applicable national, state and local laws allow subjects in this age group to consent/assent to receive contraceptive services, and
b. All applicable laws and regulations regarding the informed consent/assent of the subjects to participate in clinical trials are observed.
2. Systolic blood pressure < 130 mmHg, diastolic blood pressure < 80 mmHg at Visit 1, in sitting position after 5 minutes of rest.
3. Menstruation restarted for at least 6 months since last pregnancy (only applicable for women that were pregnant).
4. Be able and willing to provide written informed consent, or assent if the subject is an adolescent, prior to undergoing any trial-related procedures.
5. Willing to use trial contraception for thirteen 28-day cycles (LF111 arm) or to use non-hormonal contraceptive methods for the duration of the trial (non-hormonal contraceptive arm), respectively.
Are the trial subjects under 18? yes
Number of subjects for this age range: 712
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 650
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range
1. Contraindications to the use of LF111 (such as active arterial or venous thromboembolic disorders, liver tumors benign or malignant, hepatic impairment, renal impairment, adrenal insufficiency, presence or history of cervical cancer or progestin-sensitive cancers, known or suspected sex-steroid sensitive malignancies, undiagnosed abnormal uterine bleeding, undiagnosed vaginal bleeding, hypersensitivity to active substance or excipient) or adverse effects due to previous contraceptive use (for the LF111 arm only).
2. BMD Z-score below -1.5.
3. Low trauma fracture(s) defined as a fracture that results from a fall from a standing height or less, excluding fingers, toes, face and skull.
4. Medical conditions associated with low bone mass:
a. Metabolic bone disease such as osteogenesis imperfecta, Paget’s disease of the bone, osteomalacia/rickets
b. Collagen vascular diseases such as Marfan’s syndrome and Erhlos-Danlos syndrome
c. Chronic kidney disease stage 3 with estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m2 using the Bedside Schwartz equation for adolescents and the Modification of Diet in Renal Disease (MDRD) method for adult subjects
d. Gastrointestinal (malabsorptive) disease including inflammatory bowel disease, gastric bypass surgery and current postgasrectomy syndrome
e. Liver disease
f. Abnormal bone mineral metabolism (hypocalcemia/hypercalcemia, hypophosphatemia/hyperphosphatemia, hypomagnesemia).
5. In adolescents only: Short stature defined as height-for-age percentile less than the fifth percentile.
6. Use of oral, transdermal, vaginal or intrauterine hormonal contraceptives in the previous month (within the previous 3 months in case of containing estrogen) or use of injectable or implantable hormonal contraceptives in the previous 6 months.
7. Laboratory values at Screening which are considered clinically significant and which in the opinion of the investigator would be detrimental for participation in the study.
8. Ongoing pregnancy or wish for pregnancy.
9. Currently lactating or stopped lactating within the past year
10. Eating disorders (e.g., anorexia nervosa, bulimia).
11. Celiac disease.
12. Endocrine disorders (e.g., diabetes, hypothyroidism or hyperthyroidism, hyperparathyroidism, Cushing's disease).
13. Rheumatoid arthritis.
14. Current or ever use of medications or supplements known to increase BMD including bisphosphonates, denosumab, teriparatide, abaloparatide, romosozumab, calcitonin, fluoride and strontium.
15. Treatment with medications that are known to decrease bone mass:
• Glucocorticoids (oral, intravenous, chronic inhaled, chronic extensive topical) within the previous 3 months.
Note: Subjects taking chronic oral/intravenous glucocorticoids (prednisone = 2.5 mg daily for = 3 months, or the equivalent) will have a washout period of 12 months.
• Depo-medroxyprogesterone acetate within the previous 24 months (if duration of use was less than 2 years).
Note: Subjects using depo-medroxyprogesterone acetate for a duration of use greater than 2 years will be excluded.
• Aromatase inhibitors and/or raloxifene within the previous 24 months.
• Anticonvulsants (phenytoin, phenobarbital, carbamazepine and valproate), anti-retroviral protease inhibitors, cyclosporine, heparin, warfarin, thiazolidinedione, SGLT-2 inhibitors, tricyclic antidepressants, chronic proton pump inhibitor (PPI) use, selective serotonin reuptake inhibitors (SSRIs) within the previous 3 months.
16. Conditions that preclud
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: To evaluate the impact of LF111 on bone mineral density (BMD) at the lumbar spine after 12 months (13 medication cycles) of investigation in comparison to non-hormonal contraceptive methods;Secondary Objective: - To further evaluate the impact of LF111 on BMD and bone turnover after 12 months (13 medication cycles) of investigation in comparison to non-hormonal contraceptive methods<br>- To assess general safety and tolerability of LF111 in comparison to non-hormonal contraceptive methods;Primary end point(s): Cohort 1: Adolescents<br>Mean absolute change in lumbar spine (L1-L4) Z-score from baseline to 12 months as measured by dual-energy X-ray absorptiometry (DXA)<br>Cohort 2: Adults<br>Mean percentage change in lumbar spine (L1-L4) BMD from baseline to 12 months as measured by DXA;Timepoint(s) of evaluation of this end point: From baseline to 12 months
- Secondary Outcome Measures
Name Time Method Secondary end point(s): Please refer to the Protocol for Cohort 1 & 2<br>In Addition: <br>7. Changes in body weight and body mass index (BMI)<br>8. Mean absolute and relative changes in routine laboratory values from baseline to 6 months and to 12 months<br>9. Mean absolute and relative changes in serum estradiol (E2) levels in the LF111 arm from baseline to 6 months and to 12 months<br>10. Adverse events;Timepoint(s) of evaluation of this end point: From baseline to 6 months (LF111 arm only) and to 12 months<br>From baseline to 12 months